$LPCN another insider buying activity that caught my attention last week (unusual). Heavy insider buying (especially clustered buys by CEOs, CFOs, directors, or 10%+ owners) following a sharp drop in a small-cap biotech stock is often viewed as a bullish contrarian signal. Over $434,000 in insider purchases in just a few days.
Insiders have far better information on clinical pipelines, trial data, cash runway, partnerships, and regulatory timelines than the public market does. When they open their wallets after a panic sell-off, it can indicate they see the drop as overdone and believe the company is undervalued or has near-term positive catalysts ahead.
Lipocine Inc. (LPCN) is essentially debt-free with a strong cash position relative to its size, in extremely oversold levels with a potential short squeeze over $2.25 (Mega gap above that level). I took a long position for a swing trade, reason (Unusual heavy buying). Definitely on watch next Week.